Working… Menu

Phase 1 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04150497
Recruitment Status : Recruiting
First Posted : November 4, 2019
Last Update Posted : June 10, 2021
Information provided by (Responsible Party):
Cellectis S.A.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 14, 2022
Estimated Study Completion Date : October 14, 2022